About Kymera Therapeutics Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and ...

Under the terms of the Termination Agreement, all rights previously licensed to Axion, including global development and commercial rights outside Greater China, have reverted to ImmuneOnco, subject to ...

“The dosing of the first human subject using our novel formulation technology platform is yet another significant milestone for our company as we continue to advance our pipeline of innovative, ...

Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, is redefining what it means to ...

FORT LAUDERDALE, Fla., Jan. 06, 2026 (GLOBE NEWSWIRE) -- LQpay today announced the launch of Agentic AI API, a proprietary healthcare interoperability platform that enables human-like interaction with ...

Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company focused on pattern-breaking approaches that treat root causes of obesity and type 2 diabetes (“T2D”), ...

DURHAM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that CEO Anshul Thakral, CFO Jill McConnell, and SVP of ...

(Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced positive topline results from its Phase ...

In preclinical studies, ABP-102 / CT-P72 demonstrated robust antitumor activity in HER2-high tumor models, including dual xenograft models containing both HER2-high and HER2-low tumors, with selective ...

A webcast and replay of Oruka’s presentation will be available on the Oruka investor events website at Oruka Therapeutics is developing novel biologics designed to set a new standard for the ...

The positive interim results of the Phase 1a SAD/MAD trial support rapid advancement of clinical development. Aclaris expects to initiate a Phase 1b POC trial in AD imminently and a Phase 1b POC trial ...

Alesta Therapeutics, a biotechnology company focused on developing transformative small-molecule therapies for underserved diseases, provided a corporate and clinical update in advance of its ...